April 9, 2007 — MIV Therapeutics Inc. has announced that its recent bench test confirmed that merging Biosync Scientific's certified bare metal stent platform (which MIVT recently acquired) with its own polymer-free drug delivery system met critical "FDA Draft Guidance for the Submission of Research and Marketing Applications for Interventional Cardiology Devices" requirements for in vitro mechanical fatigue testing.
